Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
about
Oral budesonide for induction of remission in ulcerative colitisBudesonide Multi-matrix for the Treatment of Patients with Ulcerative ColitisTherapeutic benefits of budesonide in gastroenterologyBudesonide in the treatment of inflammatory bowel disease.Current and emerging drugs for the treatment of inflammatory bowel disease.Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity.If it walks like Crohn's and talks like Crohn's, it must be...Budesonide Use and Hospitalization Rate in Crohn's Disease: Results From a Cohort at a Tertiary Care IBD Referral Center.Long-term safety and efficacy of budesonide in the treatment of ulcerative colitisSteroid use in Crohn's disease.Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.Current Approach to the Evaluation and Management of Microscopic Colitis.Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.Budesonide-related adrenal insufficiency.Excessive weight gain is associated with an increased risk for pouch failure in patients with restorative proctocolectomy.Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis.
P2860
Q24186368-7A84D4AA-4529-4ADF-87FB-7BFC573E74CDQ26779042-B8472841-BCF5-41B9-9F97-40141C815ADEQ28281682-EF32C699-6670-45C7-A65F-45DE7552A773Q34203594-53286B76-DD3C-4792-9F53-785149F88B8DQ34883210-D720D3E1-B439-4853-A9E9-16A5DF4478D2Q36659176-77DE6B12-62D8-4706-B190-F37D4C1A3EE6Q36704021-8716761D-6DBA-42D3-AF33-FEF2C0C43E46Q37233955-790F8B29-87CB-488C-8220-7F1E783C7C04Q37577773-FFB8DA10-6427-4403-8EB4-BF6A3D67CFB3Q38188477-C00C26BD-C1E1-4182-A31B-5BBB9F74D9D0Q38196945-D4875ABF-70C8-483F-92A9-D3B14DA7C600Q38408897-882728E9-2A1A-45FB-85EB-39AA304AD31EQ39165045-8F5D4EE3-55E7-4D8D-8FA9-8AB30BDFE89EQ40396288-0D9E8F59-7F5D-4C06-848D-D5F6E09D7CECQ41634776-796F2A80-1EF6-4962-9F14-A1DE6C78C1DFQ45963829-659F2406-FBBF-4234-BB33-094D344EBE4EQ47745759-B7FB8423-D9F7-48A6-9DF7-126469AD5EC9
P2860
Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Oral budesonide for maintenanc ...... ase: a pooled safety analysis.
@en
Oral budesonide for maintenanc ...... ase: a pooled safety analysis.
@nl
type
label
Oral budesonide for maintenanc ...... ase: a pooled safety analysis.
@en
Oral budesonide for maintenanc ...... ase: a pooled safety analysis.
@nl
prefLabel
Oral budesonide for maintenanc ...... ase: a pooled safety analysis.
@en
Oral budesonide for maintenanc ...... ase: a pooled safety analysis.
@nl
P2093
P1476
Oral budesonide for maintenanc ...... ase: a pooled safety analysis.
@en
P2093
B Bengtsson
G R Lichtenstein
L Hapten-White
P Rutgeerts
P304
P356
10.1111/J.1365-2036.2008.03891.X
P407
P577
2008-11-13T00:00:00Z